AstraZeneca plc (AZN) Receives “Buy” Rating from Citigroup Inc.

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by stock analysts at Citigroup Inc. in a research report issued on Thursday, July 13th, MarketBeat Ratings reports. They presently have a GBX 6,000 ($78.14) price target on the biopharmaceutical company’s stock. Citigroup Inc.’s price target suggests a potential upside of 31.46% from the stock’s current price.

AZN has been the topic of several other reports. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.93) price target on shares of AstraZeneca plc in a research note on Friday, June 23rd. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a research note on Monday, May 22nd. J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 4,200 ($54.69) price target on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Beaufort Securities restated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, March 16th. Finally, Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a research note on Thursday, May 4th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of GBX 4,937.43 ($64.30).

AstraZeneca plc (AZN) opened at 4564.00 on Thursday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s 50 day moving average is GBX 5,022.16 and its 200-day moving average is GBX 4,861.45. The company’s market capitalization is GBX 57.78 billion.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/astrazeneca-plc-azn-given-buy-rating-at-citigroup-inc-updated-updated-updated/1198321.html.

In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.